What's Trending

A break fee in a merger-gone-south can be deducted as an ordinary expense, the U.S. Tax Court held today, finding for biopharmaceutical...

As BIO 2025 approaches in Boston, eight pivotal trends are emerging at the intersection of science, business, IP, and regulation:...

I recently had the chance to contribute to a thoughtful and timely piece by my good friend and podcast co-host, Halle Tecco. After 15...

The Centers for Medicare & Medicaid Services (CMS) has issued a new Request for Information (RFI) aimed at transforming how digital...

Last year saw growing investment in digital health startups addressing women+ health needs—but women still lag behind men when it comes...

In Actavis v. U.S., a case at the intersection of tax law and patent law, the Federal Circuit held that generic drug companies’...

In an attempt to facilitate capital raising, the SEC announced that it was expanding the ability of issuers to submit draft registration...

Life sciences M&A comes with unique challenges that require thoughtful and creative structuring. Bridging valuation gaps between buyers...

Various biotech companies have completed or launched their IPOs so far in 2025. As of early February, five sizeable life sciences...

Underscoring the exceptional value of a firm that’s purpose-built for tech and life sciences, Law360 named Fenwick a 2024 Practice Group...

On December 3, the U.S. Securities and Exchange Commission settled charges against biotherapeutics company Kiromic BioPharma, Inc., its...

After attending the 2024 Digital Health Counsel AI Summit, the transformative impact of AI and data-driven innovation on healthcare is...